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Abstract
Background: Protein mono-ADP-ribosylation is a reversible post-translational modification that modulates the function of
target proteins. The enzymes that catalyze this reaction in mammalian cells are either bacterial pathogenic toxins or
endogenous cellular ADP-ribosyltransferases. The latter include members of three different families of proteins: the well
characterized arginine-specific ecto-enzymes ARTCs, two sirtuins and, more recently, novel members of the poly(ADP-
ribose) polymerase (PARP/ARTD) family that have been suggested to act as cellular mono-ADP-ribosyltransferases. Here, we
report on the characterisation of human ARTD15, the only known ARTD family member with a putative C-terminal
transmembrane domain.
Methodology/Principal Findings: Immunofluorescence and electron microscopy were performed to characterise the sub-
cellular localisation of ARTD15, which was found to be associated with membranes of the nuclear envelope and
endoplasmic reticulum. The orientation of ARTD15 was determined using protease protection assay, and is shown to be a
tail-anchored protein with a cytosolic catalytic domain. Importantly, by combining immunoprecipitation with mass
spectrometry and using cell lysates from cells over-expressing FLAG-ARTD15, we have identified karyopherin-ß1, a
component of the nuclear trafficking machinery, as a molecular partner of ARTD15. Finally, we demonstrate that ARTD15 is a
mono-ADP-ribosyltransferase able to induce the ADP-ribosylation of karyopherin-ß1, thus defining the first substrate for this
enzyme.
Conclusions/Significance: Our data reveal that ARTD15 is a novel ADP-ribosyltransferase enzyme with a new intracellular
location. Finally, the identification of karyopherin-ß1 as a target of ARTD15-mediated ADP-ribosylation, hints at a novel
regulatory mechanism of karyopherin-ß1 functions.
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Introduction
Mono-ADP-ribosylation is a covalent, post-translational mod-
ification catalysed by bacterial toxins and eukaryotic ADP-
ribosyltransferases. These enzymes transfer the ADP-ribose moiety
from ß-NAD+ to specific amino acids of various cellular acceptor
proteins, and as a consequence affect their biological function
[1,2,3]. ADP-ribosylation was originally identified as the patho-
genic mechanism of certain bacterial toxins: the diphtheria,
cholera, pertussis and clostridia toxins are in fact mono-ADP-
ribosyltransferases known to cause various pathologies as a
consequence of their translocation into mammalian host cells
[4,5]. In mammals, enzymes structurally and functionally related
to these toxins have been identified and characterized as
intracellular or extracellular ADP-ribosyltransferases (ART)
[2,6]. These two groups of mammalian ARTs are defined as
ARTC (Clostridia-toxin-like) and ARTD (Diphtheria-toxin-like),
respectively [7]. The ARTC family includes glycosylphosphatidy-
linositol (GPI)-anchored and secreted enzymes that lead to
extracellular mono-ADP-ribosylation [6,8,9]. Four different hu-
man ARTCs have been identified (ARTC1, 3, 4, 5) of which
ARTC1 and ARTC5 are active enzymes that modify the arginine
residues of secreted and plasma membrane-associated proteins,
such as human neutrophil protein 1 (HNP1) and integrin-a7
[10,11,12]. Intracellular targets of mono-ADP-ribosylation have
also been described [13,14,15], but only in one case (glutamate
dehydrogenase; GDH) has the enzyme involved actually been
identified: SirT4 [16]. This enzyme mono-ADP-ribosylates
mitochondrial GDH thus repressing its activity [16] and conse-
quently regulating insulin secretion in pancreatic ß cells. SirT4 is a
member of a third NAD+-using family of proteins, the sirtuins,
which encode protein deacetylases [17,18]. The mammalian
mono-ADP-ribosyltransferases responsible for intracellular mono-
ADP-ribosylation are only now beginning to be identified. In
addition to the sirtuins SirT4 and SirT6, novel members of the
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implicated in intracellular mono-ADP-ribosylation [2,19,20]. The
human ARTD family includes six members (ARTD1-6), which
are typical poly-ADP-ribosyl polymerases and eleven novel poorly
characterized members (ARTD7-17) [19,20]. The typical PARPs
can transfer multiple ADP-ribose residues, and even branched
polymers of ADP-ribose, onto their target proteins, thus regulating
DNA repair, apoptosis and chromatin dynamics [19]. PARP1/
ARTD1, the founding member of this family, acts as a molecular
sensor of DNA breaks and plays a key role in the spatial and
temporal organisation of their repair [21,22]. It catalyzes both
intermolecular auto-modification and hetero-modification of
histones or proteins involved in DNA synthesis and repair
[21,22,23]. PARP/ARTD 2-6, are also poly-ADP-ribosyl poly-
merases involved in DNA repair (ARTD2 and ARTD3),
regulation of telomere length (ARTD5 and ARTD6), spindle pole
function (ARTD3, ARTD5 and ARTD6) and genotoxic response
(ARTD4) [24,25,26,27,28]. These polymerases are characterised
by the H-Y-E triad of amino-acid residues in the catalytic domain,
while the most recently identified members, ARTD7 to ARTD17,
feature variations of this motif and are unlikely to promote the
formation of ADP-ribose polymers, despite the overall similarity of
the catalytic domain [19,20]. Some of these enzymes have been
proposed to act as cellular mono-ADP-ribosyltransferases, and
indeed this has been demonstrated for ARTD10 [29]. Little is
known concerning the biological roles of these enzymes, and only
fragmented information has been obtained during recent years
[30,31,32,33,34,35].
Karyopherin-ß1/importin-ß1 (Kapß1, uniprot ID Q14974)
plays a pivotal role in the shuttling of proteins with nuclear
localisation signals (NLSs), between the cytosol and the nucleus,
through the nuclear pore complex (NPC) [36,37,38]. During this
process, Kapa (karyopherin-a/importin-a), binds to the NLS,
whereas Kapß1 binds directly to Kapa, leading to the formation of
a tri-molecular complex [39,40,41]. The complex tethers to, and
passes through the NPC by Kapß1 binding to the nucleoporins.
Once in the nucleoplasm, the complex releases the cargo protein,
and Kapß1 and Kapa are exported back to the cytosol to re-
initiate a new import cycle [37,38]. In addition to its role in
nuclear transport, Kapß1 has also been shown to participate in
regulating mitotic spindle formation [42,43]. Specifically, Kapß1
acts as a negative regulator of NuMA and TPX2, two
microtubule-associated proteins involved in the organisation of
the mitotic spindle [44,45].
Here we report on the characterization of human PARP16/
ARTD15 (herein referred to simply as ARTD15), the only known
member of the family that does not contain recognizable accessory
domains beyond the catalytic one. ARTD15 is a 36-kDa protein
containing a predicted C-terminal transmembrane tract, but no
information was available concerning its intracellular localisation
and biochemical properties. We now show that ARTD15 is an
endoplasmic reticulum-associated type IV enzyme with mono-
ADP-ribosyltransferase activity, able to interact with, and mono-
ADP-ribosylate the nuclear transport factor Kapß1.
Results
ARTD15 is Expressed in Numerous Human Cell Lines
ARTD15 with its predicted 323 amino acids is the smallest
member of the PARP/ARTD family. Unlike other ARTDs,
ARTD15 does not contain recognizable accessory domains and
only features the catalytic domain (Fig. 1A).
We first determined if the ARTD15 gene was transcribed in
various cell lines by quantitative real-time PCR (qRT-PCR). The
highest mRNA levels were found in HEK293 and HeLa cell lines
(Fig. 1B). Some of these cell lines were further analysed for protein
expression using an antibody raised against ARTD15 (Fig. 1C,
top; Fig. 1D). The protein expression levels of endogenous
ARTD15 were measured relative to those in HEK293 (Fig. 1C,
bottom panel). This is the first evidence that ARTD15 is
transcribed and that the protein is ubiquitously expressed.
ARTD15 is a Transmembrane Protein That Localises to
the Endoplasmic Reticulum
ARTD15 is the only PARP/ARTD family member with a
predicted C-terminal transmembrane (TM) domain (S288–I308;
Fig. 1A). To investigate the cellular localisation of human
ARTD15 we analyzed both endogenous (Fig. 1E) and over-
expressed (Fig. 2A) protein by immunofluorescence. A clear peri-
nuclear staining of endogenous ARTD15 and its co-localization
with the endoplasmic reticulum (ER) protein disulfide isomerase
(PDI) is shown in Figure 1E. Next, we generated an N-terminus
FLAG-tagged ARTD15 (FLAG-ARTD15), and transiently ex-
pressed it in HeLa cells that were then analyzed by immuno-
fluorescence, immuno-electron microscopy (EM) and Western
blotting. Immunofluorescence images confirmed peri-nuclear
ARTD15 localisation (Fig. 2A), while there was no detectable
FLAG staining in mock-transfected cells. Moreover, over-
expressed ARTD15 co-localised with the ER proteins calnexin
and PDI (Fig. 2A), but not with markers of other intracellular
compartments, such as the Golgi complex, mitochondria and
microtubules (Fig. 2A). Immunogold labelling and electron
microscopy confirmed ARTD15 localisation to ER and further
highlighted the association with tubular ER structures and to the
nuclear envelope (Fig. 2B). These results demonstrate that
ARTD15 resides in the ER.
To further investigate the intracellular localization of ARTD15,
we generated a deletion mutant lacking the region encompassing
the putative transmembrane domain (aminoacids 278–322;
FLAG-DTM-ARTD15). FLAG-ARTD15 and FLAG-DTM-
ARTD15 were thus transiently expressed in HeLa cells and the
sub-cellular localisation of the mutated proteins analyzed by
immunofluorescence (Fig. 3A). FLAG-DTM-ARTD15 showed a
diffuse, cytosolic localization compared with full length ARTD15
(Fig. 3A). The cytosolic localization was then confirmed by
Western Blot analysis (Fig. 3B), which confirmed that FLAG-
DTM-ARTD15 was confined to the cytosolic fraction as opposed
to the full length protein, which was found in total membranes
(Fig. 3B). Altogether, these results demonstrate that the C-terminal
region, containing the predicted transmembrane domain, is
necessary and sufficient for the localisation of ARTD15 to ER
membranes.
To analyse the orientation of ARTD15, we applied a trypsin
protease-protection assay (see Materials and Methods). To this end
we generated N-terminal and C-terminal GFP-tagged ARTD15
fusion protein. HeLa cells were transiently transfected with these
constructs and were either left untreated (control), or incubated
with digitonin to permeabilise the plasma membrane, or with
Triton X-100 to solubilise all cellular membranes. Cells were then
treated with trypsin, lysed, and finally analyzed by WB using an
anti-GFP antibody to reveal ARTD15 and two antibodies directed
against either the N- or C-terminus of calnexin (as a control).
Calnexin is a well-characterised ER type I transmembrane domain
protein with its N-terminal end facing the lumen and the C-
terminal portion in the cytoplasm [46]. As expected, the C-
terminal of calnexin was no longer detected when trypsinised after
digitonin permeabilisation, whereas its N-terminus was lost only
after Triton X-100 solubilisation, which allows trypsin to enter the
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e37352Figure 1. ARTD15 is expressed in different human cell lines. (A) Schematic diagram of ARTD15 domain structure. CD: catalytic domain; TD:
transmembrane domain. (B) Levels of ARTD15 transcript determined by qRT-PCR, normalized to GAPDH RNA and then reported as arbitrary units
relative to the ARTD15 transcript in HK2 cells (taken as 1). Data shown represent the mean (6SD) of two independent experiments performed in
triplicate. (C) Expression of ARTD15. Western blotting (WB) showing endogenous ARTD15 protein and actin levels in 50 mg protein from total cell
lysates. The expression levels of the ARTD15, normalized to actin, are shown in the histogram relative to those of HEK293 cells (taken as 100). Data
shown represent the mean (6SD) of two independent experiments performed in triplicate. (D) Ponceau S staining and Western blotting (WB) of
100 mg protein from total HEK293 cell lysate are shown. (E) Immunofluorescence staining of endogenous ARTD15 (green) in combination with PDI
(red) shows co-localization of ARTD15 protein with the ER. Bar, 20 mm.
doi:10.1371/journal.pone.0037352.g001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e37352Figure 2. ARTD15 is an ER resident protein. HeLa cells were transfected with FLAG-ARTD15. (A) Immunofluorescence staining of ARTD15
(green) in combination with the indicated markers (red) shows co-localization of ARTD15 protein with the ER. Bar, 20 mm. (B) Electron microscopy
analysis of immuno-gold staining of ARTD15 (black dots). Arrows show ER tubular structures and nuclear envelope; cellular organelles are indicated
by abbreviations (n: nucleus; pm: plasma membrane; m: mitochondria; ne: nuclear envelope). Bar, 500 nM. Data shown are representative of three
independent experiments.
doi:10.1371/journal.pone.0037352.g002
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e37352Figure 3. ARTD15 is an ER tail-anchored protein. HeLa cells were transiently transfected with full-length (ARTD15) or deleted (DTM-ARTD15)
FLAG-ARTD15 and analyzed either by (A) immuno-fluorescence microscopy with an anti-FLAG antibody; Bar, 20 mmo rb y( B) Western blotting of
total lysates (60 mg), cytosol and total membrane (30 mg) proteins using anti-FLAG antibody to visualize ARTD15 and anti-GRK2 and anti-calnexin
antibodies as a control of cell fractionation. (C) Protease protection assay performed with HeLa cells transfected with N-termini or C-termini GFP-
ARTD15. Western blotting of ARTD15 revealed with an anti-GFP antibody, and of calnexin revealed with antibodies raised against the N-termini or C-
termini of calnexin. (D) Schematic representation of ARTD15 (based on our results) and calnexin protein orientation. The N-termini (N) and C-termini
(C) of the proteins with respect to the endoplasmic reticulum are indicated. The data shown in A, B, and C are representative of at least three
independent experiments.
doi:10.1371/journal.pone.0037352.g003
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e37352Figure 4. ARTD15 is an active ADP-ribosyl transferase. (A&C ) Two mg of recombinant, purified GST-ARTD15 or GST-ARTD15-H152A/Y254A
(ARTD15 dm) were [
32P]-ADP-ribosylated in vitro in the presence of increasing concentration of NAD (as indicated in A) or with 10 mM NAD (C) and
analysed by autoradiography (AR). Ponceau red staining is a control of protein loading. (B) Recombinant, purified GST-ARTD15 (300 ng) was [
32P]-
ADP-ribosylated and analysed by autoradiography (AR). The graph indicates the picomoles of [
32P]-ADP-ribosylated ARTD15. The inset shows the
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trypsinisation resulted in the loss of its N-terminal end after mild
permeabilisation with digitonin (Fig. 3C; ARTD15). Thus the N-
terminus of ARTD15 is exposed to the cytoplasm, whereas its C-
terminus faces the ER lumen. Altogether, these data demonstrate
that, as opposed to calnexin, ARTD15 is a single pass
transmembrane protein with the N-terminal region (aa. 1–280)
positioned toward the cytoplasm, and the very short C-terminal
tail (aa. 300–322) facing the ER lumen (Fig. 3D). These results
define ARTD15 as a tail-anchored (type IV) protein.
ARTD15 is a Mono-ADP-ribosyltransferase
The ARTD family members that lack conserved residues crucial
for ADP-ribose polymer elongation have been proposed either to
be inactive enzymes (ARTD9 and ARTD13) or to act as mono-
ADP-ribosyltransferases. We thus analyzed whether ARTD15 was
indeed an active enzyme.
To this end, we purified GST-ARTD15 from Escherichia coli.
The recombinant GST-ARTD15 was tested in an in vitro ADP-
ribosylation assay using [
32P]-NAD. A main 50-kDa band,
corresponding precisely to the molecular weight of purified
GST-ARTD15 was detected (Fig. 4A). Thus, ARTD15 is able
to catalyse its auto-ADP-ribosylation, a feature typical of all
ARTC and ARTD enzymes. The GST-ARTD15 Km value for
NAD was evaluated and found to be 290+/247 mM, with a
calculated Vmax of 0,7 pmole/h/mg of purified protein (Fig. 4B).
To verify the specificity of this auto-modification, we generated a
double GST-ARTD15 H152A/Y254A mutant (ARTD15-dm;
H152 is involved in NAD binding and Y254 is the predicted
catalytic amino acid). Figure 4C shows that the ARTD15-dm
completely lacks the catalytic activity, as compared to the wild type
protein. In conclusion, ARTD15 is an active enzyme that can
catalyse its auto-ADP-ribosylation.
Next, we evaluated the activity of ARTD15 in mammalian cells
by analysing both its ability to hydrolyse [
32P]-NAD and to
transfer the ADP-ribose moiety to agmatine, a well-known model
substrate for arginine-specific mono-ADP-ribosylation (ARTC1).
To this end, HeLa cells were transiently transfected with
ARTD15; total cell membranes were then prepared and incubated
with [
32P]-NAD in the absence or presence of 1 mM agmatine.
The supernatants were analysed by TLC to monitor the hydrolysis
of the [
32P]-NAD. Figure 4D shows that ADP-ribose is generated
when [
32P]-NAD was incubated with a NAD-glycohydrolase
(NADase) (control; Fig. 4D left panel, NADase lane) but not when
incubated with ARTD15 (Fig. 4D left panel, ARTD15 lane). As
expected, agmatine was ADP-ribosylated by ARTC1 (Fig. 4D
right panel), but not by ARTD15 (Fig. 4D, right panel). This
implies that ARTD15 is an active enzyme, which however does
not catalyse ADP-ribosylation on arginine; furthermore ARTD15
does not feature NADase activity per se and thus cannot affect
NAD catabolism. In line with these conclusions, ARTD15 [
32P]-
ADP-ribosylation was not affected by the arginine-specific mono-
ADP-ribosyltransferase inhibitor MIBG [47], as instead was the
ADP-ribosylation of the Gß subunit, a well characterized target of
arginine-specific mono-ADP-ribosyltransferases [2,48,49] (Fig. 4E).
To gain further insight as to which ARTD15 amino acid is
modified by ADP-ribosylation, we investigated the chemical
stability of the ADP-ribosyl linkage. NH2OH treatment for 12 h
(which hydrolyzes the ADP-ribosylated arginine [14,50,51,52]) did
not remove the ADP-ribose of [
32P]-ADP-ribosylated ARTD15
(Fig. 4F, lane 3); this is in agreement with the fact that ARTD15 is
unable to modify agmatine (Fig. 4D, right panel) and that its
activity is not inhibited by MIBG (Fig. 4E). The same experiment
also ruled out the possibility that the ADP-ribose is linked to
glutamate since a 20-min NH2OH treatment (normally sufficient
to hydrolyze glutamate-linked ADP-ribose) did not remove ADP-
ribose from ARTD15. Finally, treatment of [
32P]-ADP-ribosylated
ARTD15 with HgCl2 (which would act on ADP-ribosylated
cysteine) was also ineffective. We did observe a 50% loss of label
upon HCl treatment (Fig. 4F, lane 4), which is known to be
effective on ADP-ribosylated serine/threonine residues [53].
Altogether, these data demonstrate that ARTD15 is an active
member of the PARP family, with auto-catalytic activity; however,
at variance with classical mono-ADP-ribosyltransferases it does not
appear to target arginine or cysteine amino acid residues.
Moreover, as opposed to PARP enzymes, ARTD15 is unable to
transfer ADP-ribose onto glutamate. The specific aminoacid
targeted by ARTD15 remains to be established.
ARTD15 Interacts with Kapß1
Having provided evidence that ARTD15 is an active ADP-
ribosyltransferase, we searched for possible interactors. To this end
HEK293 cells were transiently transfected with a plasmid
encoding for N-terminal tagged FLAG-ARTD15 or empty vector.
Total lysates from these cells were immuno-precipitated with an
anti-FLAG antibody (Fig. 5A). Two bands in the ARTD15
sample, with a molecular mass of 36 and 96 kDa, as revealed by
silver staining (Fig. 5A) were identified by MALDI-TOF-MS
analysis as ARTD15 itself and Kapß1 (Table 1). The same result
was also obtained in HeLa cells (not shown). We validated the
interaction between ARTD15 and Kapß1 by co-immunoprecip-
itation. Total lysates from HeLa cells that had been transiently
transfected with FLAG-ARTD15 were incubated with anti-Kapß1
antibody (Fig. 5B). Under these conditions, ARTD15 was co-
immunoprecipitated with endogenous Kapß1, demonstrating that
Kapß1 is an ARTD15 interactor in intact cells. We could not
detect co-immunoprecipitation of endogenous ARTD15, possibly
due to the low levels of endogenous ARTD15.
To verify whether the interaction between ARTD15 and
Kapß1 was direct, we applied a pull down assay using purified
proteins. Increasing concentrations of Kapß1 were incubated with
either GST-ARTD15 or GST alone as a control (Fig. 5C). Under
these conditions, Kapß1 specifically interacted with GST-
ARTD15 in vitro, providing evidence of a novel physical
interaction between ARTD15 and Kapß1.
Finally, we evaluated this interaction in intact cells by immuno-
fluorescence. HeLa cells were probed with antibodies against
Lineweaver-Burk analysis of the data. The data shown are the means (6SD) of four independent experiments performed in triplicate. (D) Total
membrane proteins (50 mg) obtained from HeLa cells transiently transfected with empty vector (control), ARTD15 or ARTC1, as indicated, were [
32P]-
ADP-ribosylated in vitro in the absence (left) or presence (right) of 1 mM agmatine. The supernatants and, as a further control, [
32P]-NAD (NAD) and
[
32P]-ADP-ribose (NADase) were analysed by TLC and autoradiography. The data shown are representative of at least five independent experiments.
(E) Two mg of recombinant, purified GST-ARTD15 (ARTD15) or plasma membranes added with 250 ng of purified ßc dimer (ß subunit) were ADP-
ribosylated with [
32P]-NAD
+ for 1 h at 37uC, in the presence or absence of MIBG. The loading control is shown (WB). Data shown are representative of
at least three independent experiments. (F) ADP-ribosylated ARTD15 was blotted and the filters were treated with the indicated compounds. Data
reported in the graph are the mean (6SD) of three independent experiments performed in duplicate (control: untreated sample). The inset shows a
representative experiment.
doi:10.1371/journal.pone.0037352.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e37352Figure 5. ARTD15 is a Kapß1 interactor. (A) Lysates (6 mg protein) from HeLa cells transfected with empty vector (control) or FLAG-ARTD15
were immunoprecipitated with a polyclonal anti-FLAG antibody. Proteins were separated by 10% long SDS-PAGE and proteins revealed by silver
staining. Differential proteins were excised from the gel and identified by MALDI-ToF mass spectrometry (boxed bands). (B) Cell lysates from HeLa
cells (10
6 cells/assay) transfected with FLAG-ARTD15 were immunoprecipitated with an anti-Kapß1 antibody or with control IgG. The input is shown
(1/20 of the total sample). (C) GST or GST-ARTD15 (0.1 mM) were incubated with increasing amounts of His-Kapß1. GST proteins were pulled down
with gluthathione resin. Precipitated Kapß1 protein was probed with an anti-His antibody. (D) Immunofluorescence staining of endogenous ARTD15
(green) and endogenous Kapß1 (red) in HeLa cells. Bar, 20 mm.
doi:10.1371/journal.pone.0037352.g005
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e37352ARTD15 and Kapß1. Fig. 5D shows that indeed endogenous
ARTD15 and Kapß1 co-localised, suggesting that Kapß1 most
likely interacts with the cytosolic portion of membrane bound
ARTD15.
Kapß1 is a Target of ARTD15-mediated Mono-ADP-
ribosylation
The finding that ARTD15 and Kapß1 are interacting partners,
prompted us to investigate whether Kapß1 can be ADP-
ribosylated by ARTD15. The enzymatic activity of ARTD15
towards Kapß1 was evaluated in an in vitro ADP-ribosylation
assay using recombinant proteins. His-Kapß1 was incubated with
or without GST-ARTD15 in the presence of 10 mM[
32P]-NAD
(Fig. 6A). Under these experimental conditions recombinant
Kapß1 was specifically labelled only when incubated with
ARTD15 (Fig. 6A). Thus, ARTD15 can ADP-ribosylate Kapß1.
Moreover, His-Kapß1 ADP-ribosylated with biotinylated NAD
was pulled-down with GST-ARTD15. We found that a similar
percentage (ca 50%) of both unmodified His-Kapß1 and ADP-
ribosylated His-Kapß1 interacted with ARTD15. To confirm that
Kapß1 modification is a mono-ADP-ribosylation, and not a poly-
ADP-ribosylation, we analyzed the length of the ADP-ribose chain
bound to both ARTD15 and Kapß1 following a described
procedure [54]. To this end, purified ARTD15 and Kapß1 were
ADP-ribosylated as described above. The nucleotide fraction
bound to the protein was separated by TBE-PAGE, with [
32P]-
NAD and [
32P]-ADP-ribose used as reference standards (Fig. 6B).
We found that the nucleotide fractions released from Kapß1 (lane
2–3) and from ARTD15 (lane 4) co-migrate with the single unit of
ADP-ribose obtained from mono-ADP-ribosylated agmatine (lane
6), thus confirming that the ARTD15-catalysed reactions (both
auto- and hetero-modifications) are very likely mono-and not poly-
ADP-ribosylation events. ARTD15-mediated Kapß1 mono-ADP-
ribosylation was further investigated making use of ADP-ribosyla-
tion inhibitors. Since we already knew MIBG to be ineffective, we
tested the effects of PJ34, a well-characterized inhibitor of ARTD
enzymes [55], and found that ARTD15 auto-modification and
Kapß1 mono-ADP-ribosylation were both inhibited (Fig. 6C).
Finally, the ability of ARTD15 to catalyze Kapß1 mono-ADP-
ribosylation was also evaluated using isolated membranes,
obtained from HeLa cells that had been previously transfected
with ARTD15. Figure 6D shows that in the presence of ARTD15
a 96 kDa protein was specifically labelled. This same protein was
recognized by an anti-Kapß1 antibody. We knocked-down
endogenous ARTD15 in HeLa cells by siRNA and achieved a
70% decrease in ARTD15 levels; as a consequence, Kapß1
labelling decreased 45+/212% (Fig. 6E). Altogether, these data
confirm that ARTD15 and Kapß1 interact and that Kapß1 is
specifically mono-ADP-ribosylated by ARTD15.
Discussion
Here we report on the characterization of human ARTD15,
unveiling a novel intracellular mono-ADP-ribosyltransferase.
Endogenous mono-ADP-ribosylation is believed to have important
roles in cellular signalling and regulation, however the enzymes
responsible for this intracellular mono-ADP-ribosylation remain
elusive and are only now beginning to be identified.
The human genome encodes 17 poly-ADP-ribose-polymerase
(PARP)-like genes. Many of these PARP-like proteins (ARTDs
according to the new nomenclature) however, are unlikely to carry
out genuine ADP-ribose polymer formation; this is because
although they do have a catalytic domain similar to that of
ARTD1/PARP1, they lack the catalytic glutamate residue critical
for polymerase activity [19,20,56]. A number of ARTDs (ARTD7,
ARTD8 and ARTD12) have been proposed instead to act as
cellular mono-ADP-ribosyltransferases [57], although only for
ARTD10 has this been formally demonstrated [29]. This raises
the possibility that other members of the PARP/ARTD family are
intracellular mono-ADP-ribosyltransferases.
Here we show for the first time that ARTD15 is a bona fide
mono-ADP-ribosyltransferase that catalyse auto- and hetero-
modification by transfer of a single ADP-ribose moiety. ARTD15
has a Km for NAD around 290 mM for its own ADP-ribosylation,
a value compatible with the intracellular NAD levels (ca. 500 mM).
If we consider that these estimates were obtained in a reconstituted
setting with the purified protein, it is conceivable that in
physiological conditions kinetic parameters might be more
favourable and affinity for NAD higher.
Of note, when we performed an in vitro ADP-ribosylation assay
using total membranes obtained from cells over-expressing
ARTD15, hetero-modification was the largely preferred reaction.
We also show that ARTD15 is a ubiquitous protein and appears
to be the first ADP-ribosyltransferase known to be associated with
the ER. While typical PARP enzymes are mainly nuclear, the most
recently identified members are emerging as proteins having a
mostly extra-nuclear localisation, as is the case of ARTD7,
ARTD8 and ARTD12. These are cytosolic proteins that have
been specifically identified as stress granule components, although
their cellular functions and targets remain unknown [57]. An
additional feature of ARTD15 is that it is the only ARTD family
member with a carboxy-terminal transmembrane domain and an
amino-terminal cytosolic catalytic domain. This orientation is
shared with other known tail-anchored (TA) proteins and confirms
a predictive bioinformatics study [58]. Several important protein
families are TA-proteins, including the SNAREs, which mediate
intracellular transport vesicle tethering, and the apoptotic regula-
tor Bcl-2. The role of the tail anchor varies from protein to
protein. In the case of SNAREs, for example, it is crucial for
membrane fusion; in the Bcl-2 family, the tail anchor targets
proteins to the mitochondrial outer membrane to control the
release of apoptotic factors from the inter-membrane space [59].
The role of the ARTD15 tail anchor remains to be elucidated, but
Table 1. Protein identification.
NCBI acc. number Name Score Matched peptide, no. Sequence coverage, % Molecular mass, kDa
AAH36703.1 Kapß1 127 13 20 97
AAH06389.1 ARTD15 96 9 32 36
Protein scores < 65 are significant (P,0.05).
doi:10.1371/journal.pone.0037352.t001
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32P]-ADP-ribosylated in vitro for 6 hours at 37uC in presence of
GST-ARTD15, separated by SDS-PAGE and analysed by autoradiography (AR). Recombinant proteins are shown by immunoblotting with anti-GST
(ARTD15) and anti-His antibodies. (B)[
32P]-ADP-ribosylation products derived from [
32P]-ADP-ribosylated GST-ARTD15, His-Kapß1 and from [
32P]-ADP-
ribosylated agmatine and [
32P]-NAD, as controls, were analysed by high-resolution PAGE to visualise ADP-ribose chain length. (C) GST-ARTD15 and
His-Kapß1 were [
32P]-ADP-ribosylated in vitro for 6 hours at 37uC in presence of 10 mM NAD, in presence of increasing concentration of the PARP1
inhibitor PJ34 (0.1–100 mM), separated by SDS-PAGE and analysed by autoradiography (AR). [
32P]-ADP-ribosylated PARP1 was used as control.
Immunoblotting with anti-PARP1, anti-GST (ARTD15) and anti-His (Kapß1) showed loaded protein. (D) Total membranes (50 mg) from HeLa cells
transfected with empty vector (control) or ARTD15 were [
32P]-ADP-ribosylated in vitro in presence of 10 mM NAD. Solubilised proteins were analysed
by SDS-PAGE and autoradiography (AR). The single differential target (*) was recognized with an anti-Kapß1 specific antibody (WB). WB also shows
over-expressed ARTD15, and the loading control GRASP55. The data shown are representative of five to ten experiments. (E) Quantification of [
32P]-
ADP-ribosylated Kapß1 in total membranes prepared from both control (scrambled) and ARTD15-silenced Hela cells. The data are means (6SD) of
three experiments. The inset shows an example of the inhibition of Kapß1 ADP-ribosylation (AR) and of the ARTD15 knock-down (WB). WB also shows
Kapß1, and GRASP55 as a loading control.
doi:10.1371/journal.pone.0037352.g006
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since we have identified Kapß1 as an ARTD15 interactor.
Kapß1 is a soluble receptor protein with a pivotal role in
nuclear transport [60]. In our experiments, immunofluorescence
analysis revealed that this protein co-localises with ARTD15 at the
ER and the nuclear envelope. Kapß1 was recently found to
associate with an ER-associated degradation (ERAD) transmem-
brane component (VIMP), thus supporting the hypothesis that
Kapß1 plays a functional role at the ER [61]. We found that ER-
resident ARTD15 catalyzes mono-ADP-ribosylation of Kapß1.
This mono-ADP-ribosylation has some distinguishing features: i) it
does not appear to occur on arginine, cysteine or glutamate
residue. Although at this time the targeted aminoacid remains
unknown, based on our findings we can speculate that ARTD15-
mediatedADP-ribosylation might be occurring on a serine/
threonine residue; this is at variance with the reactions catalysed
by ARTC mono-ADP-ribosyltransferases and Sirt4, which specif-
ically modify arginine and cysteine residues, respectively; ii) it is
inhibited by PJ34, a well-characterized inhibitor of ARTD
enzymes [55]. Since, however, PJ34 was described to act on the
ß-NAD+ binding pocket of PARP1/ARTD1, we can hypothesise
that it can also affect other ARTDs/PARPs having a similar
NAD+ binding pocket structure, independently from whether the
reaction catalyzed is a mono- or poly-ADP-ribosylation. iii)
Finally, ARTD15-catalysed mono-ADP-ribosylation was not
reverted by ARH1, which hydrolyzes the ADP-ribose-arginine
bond, or by ARH3, which catalyzes the hydrolysis of poly-
ADPribose and of O-acetyl-ADP-ribose (data not shown) [62,63].
In conclusion, although the specific amino acid residue remain to
be identified, the possibility exist that ARTD15 might be the first
enzyme able to ADP-ribosylate a serine/threonine residue, a
modification that had been described years ago [53]. Identification
of the precise Kapß1 modification site will require further work
and might be instrumental in defining the functional meaning of
the ARTD15-Kapß1 interaction.
We suggest that ARTD15 might be a new player in the control
of nuclear transport together with the nuclear pore complex, cargo
proteins and karyopherins [64]. Two mechanisms have been
described so far for the control of karyopherins: attenuation of
protein expression and their sequestration. Indeed, it has been
reported that poly-ADP-ribosylation of cargo proteins -but not of
karyopherins- blocks their exit from the nucleus [65]. Mono-ADP-
ribosylation of Kapß1 by ARTD15 might be a further level of
control of nuclear transport. Future work will clarify whether
ARTD15-mediated Kapß1 ADP-ribosylation can regulate Kapß1
interaction with its partners.
Materials and Methods
Cell Culture and Fractionation
Human embryonic kidney (HEK293; ATCC, CRL-1573),
epidermoid carcinoma (A431; ATCC, CRL-1555), human leuke-
mia (HL60; ATCC, CCL-240), prostate carcinoma (from a brain
metastatic site; DU145; ATCC, HTB-81), ovary adenocarcinoma
(SKOV-3; ATCC, HTB-77), colorectal carcinoma (HCT116;
ATCC, ECL-247 and HT29; ATCC, HTB-38) and breast
adenocarcinoma (MDA; ATCC, HTB-26) cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen); cervix
adenocarcinoma (HeLa; ATCC, CCL-2) cells were grown in
Modified Eagle’s medium (MEM; Invitrogen); prostate carcinoma
(from a bone metastatic site; PC3; ATCC, CRL-1435) and ovary
adenocarcinoma (OVCAR-3; ATCC, HTB-161) cells were grown
in RPMI medium; brain neuroblastoma (from a bone marrow
metastatic site; SH-SY-5; ATCC, CRL-2266), melanoma
(A375MM; obtained from Prof. Gustavo Egea, Universitat de
Barcelona, Spain [66]) and kidney (HK2; ATCC, CRL-2190) cell
lines were grown in DMEM:F12 (1:1) medium (Invitrogen); all
growth media were supplemented with 100 U/ml penicillin,
100 mg/ml streptomycin, 2 mM L-glutamine and 10% foetal
bovine serum (FBS), all from Invitrogen. Total lysates, total
membranes and cytosol fractions were prepared as previously
described [14,48]. Other reagents were purchased from Sigma-
Aldrich, unless otherwise specified.
Western Blotting and Antibodies
Cells were lysed and protein concentrations were determined
with the Bio-Rad protein assay (Bio-Rad). Samples were separated
by 10% SDS-PAGE and transferred to nitrocellulose filters (Perkin
Elmer). Blots were incubated with primary antibodies diluted in T-
TBS for 1 hour at room temperature or over-night at 4uC. After
Table 2. List of primers used in this study.
Primer name Primer sequence
ARTD15HindFor GCGAAGCTTATGCAGCCCTCAGGCTGG
ARTD15BamRev GCGGGATCCTCTTTTCGCACGATTCCAAAAG
DTM-ARTD15BamRev GCGGGATCCCTTGGGTGGCTTCTGTGAATACAC
ARTD15EcoFor GCGGAATTCATGCAGCCCTCAGGCTGG
ARTD15SalRev GCGGTCGACTCTTTTCGCACGATTCCAAAAG
ARTD15H152AFor CGAGACCTAATCTATGCATTTGCTGGTAGCCGCCTAGAAAACTTC
ARTD15H152ARev GAAGTTTTCTAGGCGGCTACCAGCAAATGCATAGATTAGGTCTCG
ARTD15Y254AFor GAGACATCCCTCCCAAGGCCTTCGTGGTCACCAATAAC
ARTD15Y254ARev GTTATTGGTGACCACGAAGGCCTTGGGAGGGATGTCTC
ARTD15qRT For GCCGTGTGTGAGGTCATTGA
ARTD15qRT Rev TTGGAATCCTTCTTCTTGGTTTG
GAPDHqRT For TGGGGCTCATTTGCAGGGG
GAPDHqRT Rev TGGATGACCTTGGCCAGGG
Restriction sites are underlined.
doi:10.1371/journal.pone.0037352.t002
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peroxidase (HRP)-conjugated secondary anti-mouse or anti-rabbit
(Calbiochem) antibodies. Protein bands were visualised with the
ECL-plus chemiluminescence reagent (GE Healthcare) according
to manufacturer’s instructions. Densitometric evaluation was
carried out with the public domain ImageJ software. The following
primary antibodies were used: rabbit anti-ARTD15, mouse anti-
GFP and rabbit anti-calnexin (C-ter) (AbCam), mouse anti-
calnexin (N-ter; BD Bioscience), mouse anti-His, rabbit anti-actin,
mouse anti-FLAG (Sigma-Aldrich), rabbit anti-biotin (Bethyl) and
rabbit anti-GRK2 (Santa Cruz). We also used our own polyclonal
antibodies against human ARTD15, rat GRASP55 and human
GST, these were raised in rabbits using GST-ARTD15, His-
GRASP55 and GST as immunogens, respectively. All were
affinity-purified on their corresponding immunogens.
Plasmids and Transfection
The pCMV-XL5 ARTD15 eukaryotic expression vector was
purchased from OriGene. The PCR product corresponding to full
length ARTD15 and DTM-ARTD15 (aa 1–277) was amplified
from the pCMV-XL5-ARTD15 vector using forward ARTD15-
HindFor and reverse ARTD15BamRev or DTM-ARTD15BamRev
primers (see Table 2). PCR products were gel-purified and
subcloned into the HindIII (59) and BamHI (39) sites of the
p3xFLAG-CMV-10, which encodes the FLAG-tag at the N-
terminus. To obtain GFP-tagged constructs, the full-length
ARTD15 PCR product obtained using ARTD15EcoFor and
ARTD15SalRev primers (see Table 2) was subcloned into the EcoRI
(59) and SalI (39) sites of pEGFP-C3 and pEGFP-N2 vectors
(Clontech). Restriction enzymes were all from New England
Biolabs. HeLa and HEK293 cells were transfected with the
different cDNAs using TransIT-LT1 transfection reagent (Mir-
usBio) according to manufacturer’s instructions. To silence
ARTD15, Hela cells were transfected with a pool of two siRNAs
(50 nM), using Lipofectamine 2000 (Invitrogen). The following
siRNAs (Qiagen) were used: 1) AACAGTCATGTTTCTCA-
TAAA; 2) TACAGCTGAAATGGAACCAAA. 70% of endoge-
nous ARTD15 was knocked down after 72 h, as evaluated by WB.
As control, the following Scrambled oligos (Sigma) were used: 1)
GCTTCCTACCACAATTTCT; 2) GGTAATCAACTAATCT-
TAA.
Site-directed Mutagenesis
Point mutations were generated using Quik Change Site-
directed mutagenesis kits (Stratagene), following the manufactur-
er’s instructions. Double mutagenesis was performed on the
pCMV-XL5-ARTD15 plasmid, using the oligonucleotides
ARTD15(H152A)For and ARTD15(H152A)Rev, and then on
the pCMV-XL5-ARTD15H152A plasmid, using the oligonucle-
otides ARTD15(Y254A)For and ARTD15(Y254A)Rev. The
oligonucleotide sequences are reported in Table 2. The construct
sequences were confirmed by automated DNA sequencing.
Protease Protection Assay
HeLa cells were plated in 12-well dishes and then transfected
with pEGFP-N3-ARTD15 or pEGFP-C2-ARTD15. Twenty-four
hours later, cells were washed with PBS and analyzed as previously
described [58], with minor modifications. Monolayers were either
left untreated or permeabilised with digitonin (100 mg/ml) in
25 mM Tris/250 mM sucrose pH 7.4 for 1,5 minutes. The
digitonin-containing solution was then removed and replaced with
trypsin (120 mg/ml) in 25 mM Tris/250 mM sucrose pH 7.4 for 3
minutes. Alternatively, cells were permeabilised with 1% Triton
X-100 in 25 mM Tris/250 mM sucrose pH 7.4 with trypsin
(120 mg/ml) for 3 minutes. Proteolysis was blocked by adding
complete protease inhibitors (Roche) at 10 fold the recommended
concentration with the addition of 1 mM phenylmethylsulfonyl
fluoride (PMSF). Total cell lysates were prepared in RIPA buffer,
separated by SDS-PAGE and immunoblotted.
RNA Extraction
RNA was isolated from the various cell lines using TRIzol
reagent (Invitrogen) according to the manufacturer’s instructions.
RNA samples were dissolved in water and quantified with a
spectrophotometer at 260 nm. Samples were treated with DNase-I
(Ambion). Total RNA (2 mg) was retro-transcribed using the
Enhanced Avian RT First Strand Synthesis Kit according to
manufacturer’s instructions (Sigma-Aldrich).
Quantitative Real-time PCR (qRT-PCR)
qRT-PCR was performed as described [67]. Primer sequences
for human ARTD15 and GAPDH genes (Table 2) were designed
using Primer Express 3.0 software (Applied Biosystems). Quanti-
tative normalization of the cDNA in each sample was carried out
using glyceraldeyde-3-phosphate dehydrogenase (GAPDH, acces-
sion number: X52123.1) amplification as internal control. Relative
quantification was done using the comparative DCT method.
Recombinant Protein Purification
To obtain the N-terminally GST-tagged construct, purified full-
length ARTD15 and ARTD15-H152A/Y254A (ARTD15-dm)
PCR products were subcloned into the pGEX-4T1 vector (GE
Healthcare) using the EcoRI (59) and SalI (39) sites. The pQE60-
Kapß1 vector encoding full-length His-Kapß1 was kindly provided
by Prof. Gino Cingolani (Department of Biochemistry and
Molecular Biology, Jefferson Medical College, Philadelphia,
USA). For GST-ARTD15 (wt and dm) production, transformed
DH5a cells were grown in Luria-Bertani medium at 37uC,
induced with 0.1 mM isopropyl-d-thiogalactoside (IPTG), and
grown for a further 16–20 h at 20uC. Purification of recombinant
GST-tagged ARTD15 (wt and dm) from the soluble lysate protein
was accomplished with Glutathione Sepharose 4B resin (GE
Healthcare) following the manufacturer’s instructions. For His-
Kapß1 purification transformed BL21 (DE3) cells (Novagen) were
grown in Luria-Bertani medium at 37uC, induced with 0.5 mM
IPTG, and grown for a further 16–20 hours at 37uC. Purification
of recombinant His-tagged Kapß1 protein from the soluble lysate
protein was accomplished with the Ni-NTA (Qiagen) affinity resin
following the manufacturer’s instructions.
Immunoprecipitation, GST-pull-down and MALDI-ToF
Analysis
HeLa or HEK293 cells were transfected with FLAG-ARTD15.
After 24 hours, cells were lysed in IP buffer (25 mM Tris-Hcl,
pH 7.5, 150 mM NaCl, 1% Triton X-100, 5 mM EDTA,
5 mM MgCl2, 1 mM DTT, 1 mM NaVO4, 40 mM ß-glycero-
phosphate) with protease inhibitors. The lysates were collected and
centrifuged at 10.000 g for 10 min at 4uC. The supernatants were
then diluted to 0.2% Triton X-100 final concentration. For
ARTD15 immunoprecipitation, total lysates from HeLa or
HEK293 cells (6 mg) were incubated over-night at 4uC with
constant rotation with anti-FLAG antibody (0.5 mg/mg lysate) or
control IgG. The samples were then incubated with a 50%
protein-A sepharose resin slurry for 2 h at 4uC with constant
rotation. Resins were centrifuged, washed five times and eluted
with Laemmli buffer. Eluates were separated by SDS-PAGE and
analysed by Silver staining. Differential protein bands were cut,
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Kapß1 immunoprecipitation, total lysates (2 mg) from HeLa cells
over-expressing FLAG-ARTD15 were incubated with an anti-
Kapß1 antibody (1 mg/mg lysate) or with the same amount of
control IgG over-night at 4uC with constant rotation. The day
after, the samples were incubated with 50 ml of a 50% protein-A
sepharose resin slurry for 2 h at 4uC with constant rotation. The
samples were then centrifuged and resins were washed 5 times in
IP buffer with 0.2% Triton X-100, and one time using IP buffer
without detergent. Resins were then eluted with 100 mlo f
Laemmli buffer, boiled for 5 minutes at 100uC and separated by
12% SDS-PAGE. Proteins were transferred to nitrocellulose
membrane for immunoblotting.
The GST-pull-down experiments were performed as previously
described (Cai et al., 2007). Briefly, His-Kapß1 was incubated
over-night at 4uC with GST or GST-ARTD15 protein in binding
buffer (50 mM Tris-Hcl, pH 7.4, 100 mM NaCl, 0.1% Triton X-
100, 0.1% NP-40 and 1 mg/ml BSA). The samples were then
incubated with a 50% Glutathione Sepharose 4B resin slurry for
2 h at 4uC with constant rotation and centrifuged at 500 g for 5
minutes. The resin was washed 5 times with washing buffer
(50 mM Tris-Hcl, pH 7.4, 100 mM NaCl) and eluted with
Laemmli buffer. The eluates were analysed by SDS-PAGE and
Western Blot.
ADP-ribosylation Assay, Thin Layer Chromatography
(TLC) and ADP-ribosylation Product Analysis
ARTD15 activity was measured by using a previously described
[
32P]-ADP-ribosylation assay [14,48]. ADP-ribosylation with
biotin-NAD (25 mM; 6-biotin-17-NAD Trevigen) was performed
as previously described [68]. The kinetic parameters were
determined by incubating 300 ng of purified GST-ARTD15 with
a fixed amount of [
32P]-NAD
+ (2 mCi) and increasing concentra-
tion of cold NAD (1–1000 mM) for 16 h at 37uC. The [
32P]-ADP-
ribosylated ARTD15 was quantified with an InstantImager
(Packard Instrument Co). Thin-layer chromatography was per-
formed as described [67]. Nucleotide were released from ADP-
ribosylated proteins as described previously [54,69] with a minor
modification: the TCA-precipitated samples were incubated in
100 ml of 10 mM Tris-NaOH, pH 12, 1 mM EDTA and 0,2 mg/
ml proteinase K at 60uC for 3 hours. The length of ADP-
ribosylation products was analysed by high-resolution gel electro-
phoresis, as described previously [54].
ADP-ribose Bond Stability
ADP-ribose-ARTD15 bond stability was examined as described
previously [70], with minor modifications. GST-ARTD15 was
[
32P]-ADP-ribosylated and electroblotted; radioactivity on the
filter was quantified with an InstantImager. The filter was then
divided into separate strips, each of which was incubated with
50 mM Hepes, 1% SDS containing either 1 mM HgCl2 at 37uC
for 1 hour, or 0.5 M NH2OH at 37uC for 20 minutes, or
1MN H 2OH at 37uC for 12 hours, or 0.2 M HCl at 37uC for 2
hours or 1 M NaCl at 37uC for 12 hours. After treatments the
filters were washed twice with water for 5 minutes and analyzed
with an InstantImager.
Indirect Immunofluorescence and Antibodies
HeLa cells were grown on coverslips in 24-well plates and
transfected with TransIT-LT1 (MirusBio, USA). Immunofluores-
cence was performed as described [67]; using an anti-FLAG
antibody (ANTI-FLAGH M2 antibody, F3165 Sigma; 1:500 in
blocking solution) and an anti-ARTD15 antibody (AbCam; 1:50 in
blocking solution) to stain ARTD15. Anti-PDI (SPA-891 Stress-
gen; 1:200 in blocking solution); anti-calnexin (BD Bioscience;
1:200 in blocking solution); and anti-Kapß1 (AbCam; 1:500 in
blocking solution) antibodies were also used as primary antibodies.
Alexa 488- and Alexa 546-conjugated goat anti-rabbit and anti-
mouse IgG (Molecular Probes; 1:400 in blocking buffer) were used
as secondary antibodies. Samples were analysed using a confocal
microscope (Zeiss LSM 510).
Electron Microscopy
HeLa cells transfected with FLAG-ARTD15 were used for
immuno-EM analysis using the gold-enhance protocol [71] and
cut as described previously [72]. Briefly, cells were fixed with 4%
formaldehyde and 0.05% glutaraldehyde for 10 min at 37uC, and
postfixed for 30 min with 4% formaldehyde alone, at room
temperature. After washing with PBS and a 20-min treatment with
a blocking solution containing 1% bovine serum albumin, 50 mM
NH4Cl and 0.2% saponin, samples were incubated with a primary
rabbit anti-FLAG antibody for 1 h. Samples were then incubated
for 2 h with nanogold-conjugated anti-rabbit IgG (Nanoprobes)
diluted in blocking solution (1:100) and extensively washed. Gold
particles were enhanced with Gold Enhancer (Nanoprobes),
according to the manufacturer’s instructions. Samples were then
fixed with 1% glutaraldehyde in 0.15 M HEPES (pH 7.3) at 37uC
for 5 min. After fixation, the cells were scraped and collected in
1.5 ml tubes. Collected cells were centrifuged and treated with 1%
OsO4 plus 1.5% potassium ferrocyanide in 0.1 M cacodylate
buffer (pH 7.3) for 1.5 h at room temperature in the dark. Samples
were then dehydrated by consecutive washes with ethanol at
increasing concentrations (50%–70%–90%–100%) and finally
embedded in Epon 812. Finally, samples were examined on a
Tecnai 12 electron microscope at 120 kW (FEI/Philips Electron
Optics).
Acknowledgments
We thank Gino Cingolani (Jefferson Medical College, Philadelphia, USA)
for providing us the pQE60-Kapß1 plasmid. We are grateful to Piera
Quesada and her lab at the University Federico II of Naples for help with
polymer size analysis. We thank Oliviano Martella for help with electron
microscopy experiments, Antonio Tamburro for help with protein
identification by MALDI-MS analysis and Elena Fontana for preparation
of Figures.
Author Contributions
Conceived and designed the experiments: SDP MDG. Performed the
experiments: SDP MM. Analyzed the data: SDP RB MDG. Contributed
reagents/materials/analysis tools: SDP GDT. Wrote the paper: SDP
MDG.
References
1. Corda D, Di Girolamo M (2003) Functional aspects of protein mono-ADP-
ribosylation. Embo J 22: 1953–1958.
2. Di Girolamo M, Dani N, Stilla A, Corda D (2005) Physiological relevance of the
endogenous mono(ADP-ribosyl)ation of cellular proteins. Febs J 272: 4565–
4575.
3. Seman M, Adriouch S, Haag F, Koch-Nolte F (2004) Ecto-ADP-ribosyltrans-
ferases (ARTs): emerging actors in cell communication and signaling. Curr Med
Chem 11: 857–872.
4. Krueger KM, Barbieri JT (1995) The family of bacterial ADP-ribosylating
exotoxins. Clin Microbiol Rev 8: 34–47.
5. Deng Q, Barbieri JT (2008) Molecular mechanisms of the cytotoxicity of ADP-
ribosylating toxins. Annu Rev Microbiol 62: 271–288.
ARTD15 Mono-ADP-Ribosylates Karyopherin-ß1
PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e373526. Moss J, Zolkiewska A, Okazaki I (1997) ADP-ribosylarginine hydrolases and
ADP-ribosyltransferases. Partners in ADP-ribosylation cycles. Adv Exp Med Biol
419: 25–33.
7. Hottiger MO, Hassa PO, Luscher B, Schuler H, Koch-Nolte F (2010) Toward a
unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem
Sci.
8. Domenighini M, Magagnoli C, Pizza M, Rappuoli R (1994) Common features
of the NAD-binding and catalytic site of ADP- ribosylating toxins. Mol
Microbiol 14: 41–50.
9. Glowacki G, Braren R, Firner K, Nissen M, Kuhl M, et al. (2002) The family of
toxin-related ecto-ADP-ribosyltransferases in humans and the mouse. Protein
Sci 11: 1657–1670.
10. Seman M, Adriouch S, Scheuplein F, Krebs C, Freese D, et al. (2003) NAD-
induced T cell death: ADP-ribosylation of cell surface proteins by ART2
activates the cytolytic P2X7 purinoceptor. Immunity 19: 571–582.
11. Paone G, Wada A, Stevens LA, Matin A, Hirayama T, et al. (2002) ADP
ribosylation of human neutrophil peptide-1 regulates its biological properties.
Proc Natl Acad Sci U S A 99: 8231–8235.
12. Zolkiewska A, Moss J (1993) Integrin alpha 7 as substrate for a glycosylpho-
sphatidylinositol- anchored ADP-ribosyltransferase on the surface of skeletal
muscle cells. J Biol Chem 268: 25273–25276.
13. Leno GH, Ledford BE (1989) ADP-ribosylation of the 78-kDa glucose-regulated
protein during nutritional stress. Eur J Biochem 186: 205–211.
14. Lupi R, Corda D, Di Girolamo M (2000) Endogenous ADP-ribosylation of the
G protein beta subunit prevents the inhibition of type 1 adenylyl cyclase. J Biol
Chem 275: 9418–9424.
15. Herrero-Yraola A, Bakhit SM, Franke P, Weise C, Schweiger M, et al. (2001)
Regulation of glutamate dehydrogenase by reversible ADP-ribosylation in
mitochondria. Embo J 20: 2404–2412.
16. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, et al.
(2006) SIRT4 inhibits glutamate dehydrogenase and opposes the effects of
calorie restriction in pancreatic beta cells. Cell 126: 941–954.
17. Tanner KG, Landry J, Sternglanz R, Denu JM (2000) Silent information
regulator 2 family of NAD- dependent histone/protein deacetylases generates a
unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci U S A 97: 14178–
14182.
18. Frye RA (2000) Phylogenetic classification of prokaryotic and eukaryotic Sir2-
like proteins. Biochem Biophys Res Commun 273: 793–798.
19. Ame JC, Spenlehauer C, de Murcia G (2004) The PARP superfamily. Bioessays
26: 882–893.
20. Otto H, Reche PA, Bazan F, Dittmar K, Haag F, et al. (2005) In silico
characterization of the family of PARP-like poly(ADP-ribosyl)transferases
(pARTs). BMC Genomics 6: 139.
21. D’Amours D, Desnoyers S, D’Silva I, Poirier GG (1999) Poly(ADP-ribosyl)ation
reactions in the regulation of nuclear functions. Biochem J 342 (Pt 2): 249–268.
22. Schreiber V, Dantzer F, Ame JC, de Murcia G (2006) Poly(ADP-ribose): novel
functions for an old molecule. Nat Rev Mol Cell Biol 7: 517–528.
23. Hassa PO, Hottiger MO (2008) The diverse biological roles of mammalian
PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front
Biosci 13: 3046–3082.
24. Boehler C, Dantzer F (2011) PARP-3, a DNA-dependent PARP with emerging
roles in double-strand break repair and mitotic progression. Cell Cycle 10:
1023–1024.
25. Chang P, Coughlin M, Mitchison TJ (2005) Tankyrase-1 polymerization of
poly(ADP-ribose) is required for spindle structure and function. Nat Cell Biol 7:
1133–1139.
26. Raval-Fernandes S, Kickhoefer VA, Kitchen C, Rome LH (2005) Increased
susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-
induced tumorigenesis. Cancer Res 65: 8846–8852.
27. Schreiber V, Ame JC, Dolle P, Schultz I, Rinaldi B, et al. (2002) Poly(ADP-
ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair
in association with PARP-1 and XRCC1. J Biol Chem 277: 23028–23036.
28. Kickhoefer VA, Siva AC, Kedersha NL, Inman EM, Ruland C, et al. (1999)
The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase.
J Cell Biol 146: 917–928.
29. Kleine H, Poreba E, Lesniewicz K, Hassa PO, Hottiger MO, et al. (2008)
Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-
ribosylation. Mol Cell 32: 57–69.
30. Kerns JA, Emerman M, Malik HS (2008) Positive selection and increased
antiviral activity associated with the PARP-containing isoform of human zinc-
finger antiviral protein. PLoS Genet 4: e21.
31. Ma Q, Baldwin KT, Renzelli AJ, McDaniel A, Dong L (2001) TCDD-inducible
poly(ADP-ribose) polymerase: a novel response to 2,3,7,8-tetrachlorodibenzo-p-
dioxin. Biochem Biophys Res Commun 289: 499–506.
32. Aguiar RC, Takeyama K, He C, Kreinbrink K, Shipp MA (2005) B-aggressive
lymphoma family proteins have unique domains that modulate transcription and
exhibit poly(ADP-ribose) polymerase activity. J Biol Chem 280: 33756–33765.
33. Goenka S, Boothby M (2006) Selective potentiation of Stat-dependent gene
expression by collaborator of Stat6 (CoaSt6), a transcriptional cofactor. Proc
Natl Acad Sci U S A 103: 4210–4215.
34. Chou HY, Chou HT, Lee SC (2006) CDK-dependent activation of poly(ADP-
ribose) polymerase member 10 (PARP10). J Biol Chem 281: 15201–15207.
35. Yu M, Schreek S, Cerni C, Schamberger C, Lesniewicz K, et al. (2005) PARP-
10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity,
inhibits transformation. Oncogene 24: 1982–1993.
36. Gorlich D, Prehn S, Laskey RA, Hartmann E (1994) Isolation of a protein that is
essential for the first step of nuclear protein import. Cell 79: 767–778.
37. Fried H, Kutay U (2003) Nucleocytoplasmic transport: taking an inventory. Cell
Mol Life Sci 60: 1659–1688.
38. Conti E, Izaurralde E (2001) Nucleocytoplasmic transport enters the atomic age.
Curr Opin Cell Biol 13: 310–319.
39. Cingolani G, Petosa C, Weis K, Muller CW (1999) Structure of importin-beta
bound to the IBB domain of importin-alpha. Nature 399: 221–229.
40. Gorlich D, Kostka S, Kraft R, Dingwall C, Laskey RA, et al. (1995) Two
different subunits of importin cooperate to recognize nuclear localization signals
and bind them to the nuclear envelope. Curr Biol 5: 383–392.
41. Gorlich D, Laskey RA (1995) Roles of importin in nuclear protein import. Cold
Spring Harb Symp Quant Biol 60: 695–699.
42. Nachury MV, Maresca TJ, Salmon WC, Waterman-Storer CM, Heald R, et al.
(2001) Importin beta is a mitotic target of the small GTPase Ran in spindle
assembly. Cell 104: 95–106.
43. Wiese C, Wilde A, Moore MS, Adam SA, Merdes A, et al. (2001) Role of
importin-beta in coupling Ran to downstream targets in microtubule assembly.
Science 291: 653–656.
44. Merdes A, Ramyar K, Vechio JD, Cleveland DW (1996) A complex of NuMA
and cytoplasmic dynein is essential for mitotic spindle assembly. Cell 87: 447–
458.
45. Wittmann T, Wilm M, Karsenti E, Vernos I (2000) TPX2, A novel xenopus
MAP involved in spindle pole organization. J Cell Biol 149: 1405–1418.
46. Wada I, Rindress D, Cameron PH, Ou WJ, Doherty JJ 2nd, et al. (1991) SSR
alpha and associated calnexin are major calcium binding proteins of the
endoplasmic reticulum membrane. J Biol Chem 266: 19599–19610.
47. Loesberg C, van Rooij H, Smets LA (1990) Meta-iodobenzylguanidine (MIBG),
a novel high-affinity substrate for cholera toxin that interferes with cellular
mono(ADP-ribosylation). Biochim Biophys Acta 1037: 92–99.
48. Dani N, Stilla A, Marchegiani A, Tamburro A, Till S, et al. (2009) Combining
affinity purification by ADP-ribose-binding macro domains with mass
spectrometry to define the mammalian ADP-ribosyl proteome. Proc Natl Acad
Sci U S A 106: 4243–4248.
49. Dani N, Mayo E, Stilla A, Marchegiani A, Di Paola S, et al. (2011) Mono-ADP-
ribosylation of the G Protein Dimer Is Modulated by Hormones and Inhibited
by Arf6. J Biol Chem 286: 5995–6005.
50. Just I, Sehr P, Jung M, van Damme J, Puype M, et al. (1995) ADP-
ribosyltransferase type A from turkey erythrocytes modifies actin at Arg-95 and
Arg-372. Biochemistry 34: 326–333.
51. Hsia JA, Tsai SC, Adamik R, Yost DA, Hewlett EL, et al. (1985) Amino acid-
specific ADP-ribosylation. Sensitivity to hydroxylamine of [cysteine(ADP-
ribose)]protein and [arginine(ADP-ribose)]protein linkages. J Biol Chem 260:
16187–16191.
52. Payne DM, Jacobson EL, Moss J, Jacobson MK (1985) Modification of proteins
by mono(ADP-ribosylation) in vivo. Biochemistry 24: 7540–7549.
53. Cervantes-Laurean D, Loflin PT, Minter DE, Jacobson EL, Jacobson MK
(1995) Protein modification by ADP-ribose via acid-labile linkages. J Biol Chem
270: 7929–7936.
54. Panzeter PL, Althaus FR (1990) High resolution size analysis of ADP-ribose
polymers using modified DNA sequencing gels. Nucleic Acids Res 18: 2194.
55. Yates SP, Taylor PL, Jorgensen R, Ferraris D, Zhang J, et al. (2005) Structure-
function analysis of water-soluble inhibitors of the catalytic domain of exotoxin A
from Pseudomonas aeruginosa. Biochem J 385: 667–675.
56. Hassa PO, Haenni SS, Elser M, Hottiger MO (2006) Nuclear ADP-ribosylation
reactions in mammalian cells: where are we today and where are we going?
Microbiol Mol Biol Rev 70: 789–829.
57. Leung AK, Vyas S, Rood JE, Bhutkar A, Sharp PA, et al. (2011) Poly(ADP-
ribose) regulates stress responses and microRNA activity in the cytoplasm. Mol
Cell 42: 489–499.
58. Kalbfleisch T, Cambon A, Wattenberg BW (2007) A bioinformatics approach to
identifying tail-anchored proteins in the human genome. Traffic 8: 1687–1694.
59. Borgese N, Fasana E (2011) Targeting pathways of C-tail-anchored proteins.
Biochim Biophys Acta 1808: 937–946.
60. Harel A, Forbes DJ (2004) Importin beta: conducting a much larger cellular
symphony. Mol Cell 16: 319–330.
61. Zhong Y, Wang Y, Yang H, Ballar P, Lee JG, et al. (2011) Importin Interacts
with the Endoplasmic Reticulum-associated Degradation Machinery and
Promotes Ubiquitination and Degradation of Mutant {alpha}1-Antitrypsin.
J Biol Chem 286: 33921–33930.
62. Oka S, Kato J, Moss J (2006) Identification and characterization of a
mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J Biol Chem 281: 705–
713.
63. Ono T, Kasamatsu A, Oka S, Moss J (2006) The 39-kDa poly(ADP-ribose)
glycohydrolase ARH3 hydrolyzes O-acetyl-ADP-ribose, a product of the Sir2
family of acetyl-histone deacetylases. Proc Natl Acad Sci U S A 103: 16687–
16691.
64. Terry LJ, Shows EB, Wente SR (2007) Crossing the nuclear envelope:
hierarchical regulation of nucleocytoplasmic transport. Science 318: 1412–1416.
ARTD15 Mono-ADP-Ribosylates Karyopherin-ß1
PLoS ONE | www.plosone.org 14 June 2012 | Volume 7 | Issue 6 | e3735265. Kanai M, Hanashiro K, Kim SH, Hanai S, Boulares AH, et al. (2007) Inhibition
of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation.
Nat Cell Biol 9: 1175–1183.
66. Kozlowski JM, Hart IR, Fidler IJ, Hanna N (1984) A human melanoma line
heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl
Cancer Inst 72: 913–917.
67. Stilla A, Di Paola S, Dani N, Krebs C, Arrizza A, et al. (2011) Characterisation
of a novel glycosylphosphatidylinositol-anchored mono-ADP-ribosyltransferase
isoform in ovary cells. Eur J Cell Biol 90: 665–677.
68. Zhang J (1997) Use of biotinylated NAD to label and purify ADP-ribosylated
proteins. Methods Enzymol 280: 255–265.
69. Malanga M, Althaus FR (2011) Noncovalent protein interaction with poly(ADP-
ribose). Methods Mol Biol 780: 67–82.
70. Piron KJ, McMahon KK (1990) Localization and partial characterization of
ADP-ribosylation products in hearts from adult and neonatal rats. Biochem J
270: 591–597.
71. Polishchuk RS, Mironov AA (2001) Correlative video light/electron microscopy.
Curr Protoc Cell Biol Chapter 4: Unit 4 8.
72. Polishchuk VP, Tyvonchuk TP, Rengevich Ie V, Beketov GV, Budzanivskaia
IG, et al. (2000) [Use of atomic force microscopy to study the morphology and
structure of viruses]. Mikrobiol Z 62: 40–43.
ARTD15 Mono-ADP-Ribosylates Karyopherin-ß1
PLoS ONE | www.plosone.org 15 June 2012 | Volume 7 | Issue 6 | e37352